The highly virulent influenza virus that appeared in chickens in Pennsylvania in 1983 illustrates the potential threat of influenza to animnals as well as to humans. The virus was devastating to chickens, causing up to 80% mortality among chickens on some farms and high mortality among turkeys and guinea fowl. The outbreak of disease was caused by an influenza A virus ofthe H5 subtype [A/Chicken/Pennsylvania! 1370/83 (H5N2)] (Chick/Penn). Viruses of this hemagglutinin subtype include A/Tern/South Africa/61 (H5N3) (2) and A/Chicken/Scotland/59 (H5N1) (15) , which have also caused high mortality among birds. To eradicate this disease outbreak, quarantine measures were instituted and a state and federal task force -was formed to depopulate farms of infected birds. The virus has apparently been eradicated from domestic poultry as a result of the depopulation, in which over 17 million birds were slaughtered at a cost of approximately $61 million.
Amantadine hydrochloride (1-adamantanamine hydrochloride) and rimantadine hydrochloride (methyl-iadamantanemethylamine hydrochloride) are effective chemotherapeutic agents in the prophylaxis of influenza A infections in humans (4, 8, 13, 19, 20) . Efficacy rates of 85% for rimantadine and 91% for amantadine have been reported. Amantadine has also been shown to be effective against influenza A virus infection of horses (3), quail (5), and turkeys (10) . In turkeys treated with daily doses of amantadine, infection was prevented or remained subclinical in 80% of birds infected with a highly virulent influenza A virus (10) . The appearance of a highly pathogenic virus in chickens in Pennsylvania in October 1983 provided an opportunity for evaluation of these chemotherapeutic agents.
The studies indicate that amantadine and rimantadine are efficacious but that resistant variants of the virus arise, are transmitted to other chickens in contact with the infected birds, and cause mortality. Vaccine plus chemotherapeutic agents prevented the appearance of resistant mutants.
MATERIALS AND METHODS
Viruses and vaccine, The virulent Chick/Penn virus iso- Infection and treatment of animals. White Leghorn chickens (5 to 6 weeks old) and adult laying hens (>6 months old) were used in these studies. The birds were housed in our P3 containment facility in air-filtered compartments.
Groups of chickens were infected by dropping 0. (11) .
RESULTS
Chemotherapeutic agents and their excretion. Since commercial chicken farms frequently contain more than 50,000 birds, a method for mass application of the chemotherapeutic agent was investigated. Both amantadine and rimantadine are stable and water soluble (7), and so they were adminis- tered in the drinking water. Amantadine (0.01%) supplied in drinking water was rapidly absorbed by the body; by 24 h, significant levels were present in serum (354 ng/ml), muscle (688 ng/g), and liver (2,560 ng/g). The levels increased slightly by day 2 and were maintained; after removal of the drug, the levels in serum and tissue fell almost to zero within 24 h but the level in the white and yolk (2,450 ng/g) of eggs was maintained for at least 3 days. Prophylactic evaluation. To investigate the prophylactic value of these drugs, young birds (5 to 8 weeks old) and adult laying hens were inoculated with virus, and the chemotherapeutic agent was administered simultaneously. In young birds, neither agent was well accepted at the 0.1% level (Table 1) , water intake decreased, and the birds showed a reduction in weight gain as compared with the controls. Despite the poor acceptance of the agents, none of the birds showed clinical signs of infection, and virus was not isolated. At the 0.01% level, both rimantadine and Therapeutic evaluation. Studies were done to determine whether amantadine was efficacious if administered subsequent to virus inoculation (Table 2) . Amantadine was effective in young birds (5 to 6 weeks); the majority of birds (7/8) infected 24 or 48 h before administration of the drug survived, and half of the birds (2/4) infected 72 h before treatment survived. Most of the birds were listless from days 4 to 8 postinoculation and shed virus in their feces for up to 10 days but recovered and developed high levels of antibodies (HI titer of > 1,000). Adult birds infected with Chick/Penn virus before administration of amantadine gave similar results. The level of virus shed in the feces of untreated adult birds was as high as 107 3 EID50/g, and similar levels of virus were shed by amantadine-treated birds.
Transmission. The above experiments demonstrate that amantadine is effective in the treatment of chickens experimentally infected with the virulent Chick/Penn influenza virus but did not prevent virus shedding. The experiments do not mimic natural exposure, and the question remained whether the virus shed in the presence of amantadine would be transmissible to other drug-treated birds. To emulate field conditions, adult laying hens were inoculated with virus, and 48 h later two infected birds were moved to cages containing 10 susceptible birds; all birds were then given amantadine (0.01%) in their water (Table 3) . None of the infected birds developed signs of disease, but half of the contacts (25/50) developed severe signs of disease at 9 to 20 days later, and the majority (15/25) of these birds died after developing the severe clinical signs described above. Similar results were obtained when rimantadine was used in transmission studies (results not shown). All of the surviving birds developed high levels of antibodies, indicating that all of the contacts had been infected. The virus recovered from these birds was resistant to amantadine in the plaque assay described by Appleyard (1), and 0.01% amantadine did not prevent infection of chickens with 104 EID50 of this virus (results not shown). Previous studies have shown that amantadineresistant strains occur at a relatively high frequency (0.1 to 0.04%), both in vitro and in vivo under laboratory conditions (8, 12, 14) .
Efficacy of chemotherapy and vaccination. Studies were done to determine whether vaccine administered at the time of contact would prevent transmission of the amantadineresistant strains. Vaccine alone did not reduce mortality among the contacts, but when vaccine and amantadine treatment were administered simultaneously none of these birds died and they all developed antibody (Table 3 ). The dose of vaccine required to protect the birds was high; 9 or 18 jig of HA protein per dose plus 0.01% amantadine completely protected the birds, whereas lower doses of vaccine (3 ,ug of HA per dose) protected only half the birds. The dose of vaccine required to protect chickens (9 to 18 ,ug of HA per dose) under these conditions was of the same order as that required to protect humans (8 to 15 ,ug per dose [16] ). Birds treated with vaccine alone or vaccine plus amantadine developed nearly identical levels of antibodies, indicating that amantadine does not interfere with the development of antibodies (Table 3 ).
DISCUSSION
In the initial studies, amantadine and rimantadine showed considerable promise as prophylactic agents in the treatment of highly virulent Chick/Penn influenza virus. However, under conditions simulating natural transmission of the virus, amantadine-resistant mutant viruses arose within 9 days; all of the contacts were infected and approximately 50% died. Simultaneous administration of H5N2 vaccine and amantadine protected the birds from infection, whereas vaccine alone did not. The efficacy of vaccine plus chemotherapeutic agent can be explained by the rapid response of chickens to vaccination with influenza virus. By the time amantadine-resistant viruses appeared (approximately 9 days after initial infection), the birds were immune. These results indicate that after the appearance of a highly virulent influenza virus outbreak, amantadine plus vaccine would be a viable option, especially under conditions when eradication is not a viable option.
Amantadine is believed to inhibit influenza virus replication by interfering with an early stage of virus growth; uncoating (9) and transcription by the polymerase of the infecting virus particles are prevented (17) . It is possible that amantadine inhibits replication by raising the pH of the endosome and preventing the conformational change in the HA that is necessary for fusion (18) . On the other hand, resistance has been associated with the matrix protein (12) and can be segregated independently of the HA and neuraminidase (1, 12) , indicating that further studies are needed on the mode of action of this drug (17) . Continued shedding of high doses of virus (up to 107 3 EID5o/g) in the feces of amantadine-treated birds (which were infected 2 days before administration of the drug) also suggests that amantadine has other modes of action; this agent was surprisingly efficacious when used therapeutically.
It is probable that another outbreak of highly virulent influenza will occur in humans; the last severe outbreak occurred in 1918 to 1919. The question of the value of chemotherapeutic agents arises in the face of such an epidemic. Although amantadine-resistant viruses have been isolated with a high frequency in laboratory studies, resistant VOL. 55, 1985 viruses have not been reported in human trials. Although the site of influenza virus replication in avian species (intestinal) differs from that in mammals (respiratory), the possibility exists that during a severe epidemic of influenza, resistant strains might emirge and cause disease as they did in the present study. The high rate of emergence of amantadineresistant strains would be a great disadvantage, but at this time these drugs offer the only possible approach to controlling a highly virulent new human influenza virus strain. If the chemotherapy-plus-vaccine approach is to be considered for the control of highly virulent influenza virus in humans or lower animals, it would have to be initiated before drugresistant viruses reached an epidemic level; otherwise, the approach would have no advantage over vaccine alone.
